Date: 2014-04-30
Type of information: Grant
Company: Oxford BioMedica (UK)
Investors: BioMedical Catalyst Fund (UK)
Amount: £2.2 million (€2.68 million)
Funding type: grant
Planned used: The grant will help fund a Phase I/II clinical trial of OXB-102 in Parkinson’s disease patients.Using Oxford BioMedica’s proprietary LentiVector® gene delivery technology, OXB-102 delivers the genes for three enzymes which are critical for the biosynthesis of dopamine. OXB-102 is a new, more potent, form of ProSavin® which completed a Phase I/II clinical trial in 2012, the results of which were published in January 2014 in The Lancet. ProSavin® demonstrated a favourable safety profile and a statistically significant improvement in motor function at six and 12 months post-treatment relative to baseline. OXB-102 has been developed to increase the likelihood of success in later stages of development and future commercialisation. Pre-clinical efficacy studies carried out in 2013 indicate that OXB-102 is at least five times more potent than ProSavin®.
Others: * On April 30, 2014, Oxford BioMedica, a UK gene-based biopharmaceutical company, has announced it has been awarded a £2.2 million grant by the UK\'s innovation agency, the Technology Strategy Board under the Biomedical Catalyst funding programme. This award will help fund a Phase I/II clinical trial of OXB-102 in Parkinson’s disease patients. The funding award is subject to due diligence and final confirmation by the Technology Strategy Board. Further details will be disclosed in due course.
Therapeutic area: Neurodegenerative diseases
